Information Provided By:
Fly News Breaks for October 10, 2018
MYGN
Oct 10, 2018 | 04:59 EDT
Piper Jaffray analyst William Quirk upgraded Myriad Genetics to Overweight and raised his price target for the shares to $53 from $38. After updating his reimbursement model for Myriad's Prolaris, Vectra, and GeneSight, the analyst believes the company has $9 of earnings per share power. Quirk now has increased confidence in Myriad's ability to beat Street expectations and admits he's been wrong on the shares.
News For MYGN From the Last 2 Days
There are no results for your query MYGN